$13.3 Billion is the total value of Baker Brothers Advisors's 119 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Buy | Seattle Genetics, Inc. | $3,388,948,000 | +30.6% | 51,046,060 | +3.0% | 25.46% | +15.8% |
| INCY | Buy | Incyte Corporation | $2,294,819,000 | -19.5% | 34,251,034 | +0.1% | 17.24% | -28.7% |
| BGNE | Buy | BeiGene, Ltd.sponsored adr | $1,838,584,000 | +87.7% | 11,959,824 | +105.2% | 13.82% | +66.4% |
| ALXN | Alexion Pharmaceuticals, Inc. | $1,062,214,000 | +11.4% | 8,555,894 | 0.0% | 7.98% | -1.3% | |
| BMRN | BioMarin Pharmaceutical Inc. | $714,327,000 | +16.2% | 7,583,084 | 0.0% | 5.37% | +3.0% | |
| GHDX | Buy | Genomic Health, Inc. | $695,045,000 | +61.1% | 13,790,574 | +0.0% | 5.22% | +42.8% |
| ACAD | ACADIA Pharmaceuticals Inc. | $415,777,000 | -32.0% | 27,228,338 | 0.0% | 3.12% | -39.8% | |
| MDGL | Buy | Madrigal Pharmaceuticals, Inc. | $327,035,000 | +354.8% | 1,169,278 | +89.9% | 2.46% | +303.4% |
| HRTX | Heron Therapeutics, Inc. | $195,233,000 | +40.8% | 5,025,298 | 0.0% | 1.47% | +24.7% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $188,741,000 | +1.7% | 2,837,352 | 0.0% | 1.42% | -9.9% | |
| MRTX | Sell | Mirati Therapeutics, Inc. | $123,914,000 | +58.3% | 2,513,462 | -1.4% | 0.93% | +40.4% |
| ONCE | Spark Therapeutics, Inc. | $114,551,000 | +24.3% | 1,384,130 | 0.0% | 0.86% | +10.2% | |
| DBVT | DBV Technologies S.A.sponsored adr | $106,279,000 | -16.4% | 5,509,560 | 0.0% | 0.80% | -25.8% | |
| SAGE | Sell | Sage Therapeutics, Inc. | $96,000,000 | -7.9% | 613,300 | -5.2% | 0.72% | -18.3% |
| ARRY | Array BioPharma Inc. | $94,911,000 | +2.8% | 5,656,196 | 0.0% | 0.71% | -8.8% | |
| NBIX | Neurocrine Biosciences, Inc. | $92,800,000 | +18.5% | 944,624 | 0.0% | 0.70% | +5.0% | |
| RYTM | Buy | Rhythm Pharmaceuticals, Inc. | $84,658,000 | +107.6% | 2,708,200 | +32.2% | 0.64% | +83.8% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $80,290,000 | +20.1% | 14,012,172 | 0.0% | 0.60% | +6.3% | |
| ARGX | argenx SEsponsored adr | $79,691,000 | +3.0% | 961,754 | 0.0% | 0.60% | -8.7% | |
| CERS | Cerus Corporation | $71,702,000 | +21.7% | 10,749,937 | 0.0% | 0.54% | +8.0% | |
| AMRN | Amarin Corporation plcsponsored adr new | $70,049,000 | +2.7% | 22,669,509 | 0.0% | 0.53% | -9.0% | |
| CBAY | Buy | CymaBay Therapeutics, Inc. | $65,996,000 | +29.7% | 4,917,700 | +25.5% | 0.50% | +15.1% |
| NVTA | Invitae Corporation | $61,736,000 | +56.7% | 8,399,411 | 0.0% | 0.46% | +38.9% | |
| KNSA | New | Kiniksa Pharmaceuticals, Ltd. | $52,050,000 | – | 3,000,000 | +100.0% | 0.39% | – |
| IDRA | New | Idera Pharmaceuticals, Inc. | $51,024,000 | – | 38,654,811 | +100.0% | 0.38% | – |
| TCDA | New | Tricida, Inc. | $47,840,000 | – | 1,600,000 | +100.0% | 0.36% | – |
| GWPH | Buy | GW Pharmaceuticals plcads | $44,904,000 | +79.7% | 321,800 | +45.1% | 0.34% | +59.0% |
| Sell | Novavax, Inc.note 3.75% 2/1/23 | $42,667,000 | -31.0% | 73,500,000 | -16.9% | 0.32% | -38.7% | |
| ABEO | Abeona Therapeutics Inc. | $34,950,000 | +11.5% | 2,184,364 | 0.0% | 0.26% | -1.1% | |
| ERYP | Sell | ERYTECH Pharma S.A.sponsored adr | $34,470,000 | -46.9% | 3,085,969 | -0.1% | 0.26% | -52.9% |
| XNCR | Xencor, Inc. | $32,275,000 | +23.4% | 872,072 | 0.0% | 0.24% | +9.5% | |
| ECYT | Endocyte, Inc. | $31,434,000 | +51.8% | 2,277,799 | 0.0% | 0.24% | +34.9% | |
| BLUE | bluebird bio, Inc. | $31,390,000 | -8.1% | 200,000 | 0.0% | 0.24% | -18.3% | |
| BLCM | Sell | Bellicum Pharmaceuticals, Inc. | $30,210,000 | +10.9% | 4,093,447 | -1.4% | 0.23% | -1.7% |
| AQXP | Aquinox Pharmaceuticals, Inc. | $28,976,000 | -81.2% | 10,934,154 | 0.0% | 0.22% | -83.3% | |
| MRUS | Merus N.V. | $26,402,000 | +22.8% | 1,160,014 | 0.0% | 0.20% | +8.8% | |
| GLPG | Galapagos NVsponsored adr | $23,957,000 | -7.6% | 259,894 | 0.0% | 0.18% | -18.2% | |
| QURE | Buy | uniQure N.V. | $22,869,000 | +94.6% | 605,000 | +21.0% | 0.17% | +72.0% |
| HALO | Sell | Halozyme Therapeutics, Inc. | $21,660,000 | -30.1% | 1,283,929 | -18.8% | 0.16% | -38.0% |
| MYOK | Buy | MyoKardia, Inc. | $21,504,000 | +51.8% | 433,121 | +49.2% | 0.16% | +35.0% |
| SLDB | Solid Biosciences Inc. | $20,946,000 | +375.1% | 587,884 | 0.0% | 0.16% | +324.3% | |
| ZYME | New | Zymeworks Inc. | $19,378,000 | – | 1,311,085 | +100.0% | 0.15% | – |
| SGMO | Sell | Sangamo Therapeutics, Inc. | $18,232,000 | -40.3% | 1,283,923 | -20.1% | 0.14% | -47.1% |
| AIMT | Aimmune Therapeutics, Inc. | $18,121,000 | -15.5% | 673,908 | 0.0% | 0.14% | -25.3% | |
| INSM | Insmed Incorporated | $16,555,000 | +5.0% | 700,000 | 0.0% | 0.12% | -7.5% | |
| CFRX | ContraFect Corporation | $15,808,000 | +36.0% | 7,153,076 | 0.0% | 0.12% | +20.2% | |
| CMTA | Buy | Clementia Pharmaceuticals Inc. | $15,695,000 | +314.3% | 1,192,595 | +377.0% | 0.12% | +268.8% |
| BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $15,198,000 | +7.8% | 15,000,000 | 0.0% | 0.11% | -5.0% | ||
| BOLD | Audentes Therapeutics, Inc. | $15,025,000 | +27.2% | 393,222 | 0.0% | 0.11% | +13.0% | |
| NTLA | Sell | Intellia Therapeutics, Inc. | $14,964,000 | -14.9% | 546,922 | -34.4% | 0.11% | -24.8% |
| AGLE | Buy | Aeglea BioTherapeutics, Inc. | $14,684,000 | +30.1% | 1,387,872 | +22.0% | 0.11% | +14.6% |
| New | Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $14,466,000 | – | 10,000,000 | +100.0% | 0.11% | – | |
| BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $13,000,000 | +3.7% | 12,228,000 | 0.0% | 0.10% | -7.5% | ||
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $11,301,000 | +7.9% | 3,621,962 | -17.3% | 0.08% | -4.5% |
| EXEL | Sell | Exelixis, Inc. | $11,049,000 | -57.1% | 513,410 | -55.8% | 0.08% | -61.9% |
| Corsicanto II Designated Activity Companynote 3.5% 1/5/2047 | $10,908,000 | -1.1% | 10,000,000 | 0.0% | 0.08% | -11.8% | ||
| ALBO | Albireo Pharma, Inc. | $8,875,000 | +9.0% | 250,000 | 0.0% | 0.07% | -2.9% | |
| IFRX | Buy | InflaRx N.V. | $8,347,000 | +44.7% | 258,824 | +29.4% | 0.06% | +28.6% |
| XLRN | Acceleron Pharma Inc. | $7,952,000 | +24.1% | 163,900 | 0.0% | 0.06% | +11.1% | |
| PGNX | Sell | Progenics Pharmaceuticals, Inc. | $7,871,000 | -54.2% | 979,016 | -57.5% | 0.06% | -59.6% |
| GLMD | New | Galmed Pharmaceuticals Ltd. | $7,570,000 | – | 636,140 | +100.0% | 0.06% | – |
| FOMX | Sell | Foamix Pharmaceuticals Ltd. | $7,466,000 | -9.0% | 1,490,201 | -6.8% | 0.06% | -20.0% |
| GTHX | G1 Therapeutics, Inc. | $7,366,000 | +17.3% | 169,492 | 0.0% | 0.06% | +3.8% | |
| AUTL | New | Autolus Therapeutics plcspon ads | $6,304,000 | – | 235,294 | +100.0% | 0.05% | – |
| MNTA | Momenta Pharmaceuticals, Inc. | $6,309,000 | +12.7% | 308,500 | 0.0% | 0.05% | 0.0% | |
| Aegerion Pharmaceuticals, Inc.note 2% 8/15/2019 | $6,027,000 | -17.1% | 9,517,000 | 0.0% | 0.04% | -27.4% | ||
| ASMB | Sell | Assembly Biosciences, Inc. | $5,826,000 | -38.8% | 148,587 | -23.3% | 0.04% | -45.7% |
| VNDA | Sell | Vanda Pharmaceuticals Inc. | $5,912,000 | -41.6% | 310,354 | -48.3% | 0.04% | -48.8% |
| SYRS | Syros Pharmaceuticals, Inc. | $5,869,000 | -21.3% | 574,835 | 0.0% | 0.04% | -30.2% | |
| MNLO | Menlo Therapeutics Inc. | $5,684,000 | -78.4% | 700,000 | 0.0% | 0.04% | -80.7% | |
| ACHN | Sell | Achillion Pharmaceuticals, Inc. | $5,500,000 | -48.1% | 1,943,620 | -32.0% | 0.04% | -54.4% |
| CCXI | ChemoCentryx, Inc. | $5,453,000 | -3.2% | 414,029 | 0.0% | 0.04% | -14.6% | |
| ANAB | Sell | AnaptysBio, Inc. | $5,192,000 | -45.2% | 73,086 | -19.8% | 0.04% | -51.2% |
| SESN | New | Sesen Bio, Inc. | $5,118,000 | – | 2,624,412 | +100.0% | 0.04% | – |
| VSAR | Buy | Versartis, Inc. | $4,913,000 | +108.8% | 2,426,310 | +70.1% | 0.04% | +85.0% |
| ACOR | New | Acorda Therapeutics, Inc. | $4,968,000 | – | 173,100 | +100.0% | 0.04% | – |
| GLYC | Sell | GlycoMimetics, Inc. | $4,697,000 | -48.6% | 291,214 | -48.3% | 0.04% | -54.5% |
| GNMX | Aevi Genomic Medicine, Inc. | $4,501,000 | -44.8% | 4,055,142 | 0.0% | 0.03% | -50.7% | |
| LJPC | La Jolla Pharmaceutical Company | $4,512,000 | -2.0% | 154,675 | 0.0% | 0.03% | -12.8% | |
| MGNX | Sell | MacroGenics, Inc. | $4,495,000 | -50.9% | 217,695 | -40.1% | 0.03% | -56.4% |
| ADMS | Adamas Pharmaceuticals, Inc. | $4,459,000 | +8.1% | 172,630 | 0.0% | 0.03% | -2.9% | |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $4,422,000 | -22.9% | 373,144 | 0.0% | 0.03% | -32.7% | |
| NTRA | Natera, Inc. | $4,304,000 | +103.0% | 228,676 | 0.0% | 0.03% | +77.8% | |
| APLS | New | Apellis Pharmaceuticals, Inc. | $4,314,000 | – | 196,078 | +100.0% | 0.03% | – |
| ALKS | Alkermes plc | $4,126,000 | -29.0% | 100,251 | 0.0% | 0.03% | -36.7% | |
| AERI | Sell | Aerie Pharmaceuticals, Inc. | $4,063,000 | -65.3% | 60,155 | -72.1% | 0.03% | -68.7% |
| FTSV | New | Forty Seven, Inc. | $4,000,000 | – | 250,000 | +100.0% | 0.03% | – |
| TTPH | Tetraphase Pharmaceuticals, Inc. | $3,338,000 | +16.3% | 935,000 | 0.0% | 0.02% | +4.2% | |
| Nabriva Therapeutics plc | $3,265,000 | -30.8% | 938,235 | 0.0% | 0.02% | -37.5% | ||
| Buy | Trillium Therapeutics Inc. | $3,071,000 | +4.2% | 511,763 | +25.0% | 0.02% | -8.0% | |
| TNXP | Tonix Pharmaceuticals Holdings Corp. | $3,113,000 | +48.4% | 699,500 | 0.0% | 0.02% | +27.8% | |
| KRYS | Krystal Biotech, Inc. | $2,974,000 | +47.4% | 200,000 | 0.0% | 0.02% | +29.4% | |
| RIGL | Sell | Rigel Pharmaceuticals, Inc. | $2,948,000 | -66.9% | 1,041,612 | -58.6% | 0.02% | -71.1% |
| NLNK | NewLink Genetics Corporation | $2,415,000 | -34.3% | 507,273 | 0.0% | 0.02% | -41.9% | |
| OVID | Ovid Therapeutics Inc. | $1,932,000 | +10.3% | 247,733 | 0.0% | 0.02% | 0.0% | |
| RARX | Ra Pharmaceuticals, Inc. | $1,771,000 | +87.4% | 177,952 | 0.0% | 0.01% | +62.5% | |
| MDWD | MediWound Ltd. | $1,559,000 | +32.7% | 226,000 | 0.0% | 0.01% | +20.0% | |
| CLLS | Cellectis S.A.sponsored ads | $1,415,000 | -10.2% | 50,000 | 0.0% | 0.01% | -15.4% | |
| RCUS | New | Arcus Biosciences, Inc. | $1,488,000 | – | 121,534 | +100.0% | 0.01% | – |
| TRVN | Trevena, Inc. | $1,368,000 | -12.2% | 950,000 | 0.0% | 0.01% | -23.1% | |
| ABUS | Arbutus Biopharma Corporation | $1,318,000 | +46.0% | 180,582 | 0.0% | 0.01% | +25.0% | |
| DVAX | Dynavax Technologies Corporation | $1,144,000 | -23.2% | 75,000 | 0.0% | 0.01% | -30.8% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $1,180,000 | -22.1% | 556,665 | 0.0% | 0.01% | -30.8% | |
| SELB | Selecta Biosciences, Inc. | $1,242,000 | +30.1% | 93,750 | 0.0% | 0.01% | +12.5% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $1,187,000 | +5.7% | 100,000 | 0.0% | 0.01% | -10.0% | |
| CRBP | Sell | Corbus Pharmaceuticals Holdings, Inc. | $1,250,000 | -69.0% | 247,450 | -62.5% | 0.01% | -73.5% |
| INFI | Infinity Pharmaceuticals, Inc. | $1,109,000 | -9.0% | 580,400 | 0.0% | 0.01% | -20.0% | |
| JNCE | Jounce Therapeutics, Inc. | $766,000 | -65.7% | 100,000 | 0.0% | 0.01% | -68.4% | |
| TTOO | T2 Biosystems, Inc. | $774,000 | +19.3% | 100,000 | 0.0% | 0.01% | 0.0% | |
| PRTO | Proteon Therapeutics, Inc. | $732,000 | -1.9% | 298,591 | 0.0% | 0.01% | 0.0% | |
| BDSI | BioDelivery Sciences International, Inc. | $620,000 | +31.1% | 210,021 | 0.0% | 0.01% | +25.0% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $720,000 | -5.5% | 279,999 | 0.0% | 0.01% | -16.7% | |
| STML | Sell | Stemline Therapeutics, Inc. | $715,000 | -83.8% | 44,524 | -84.5% | 0.01% | -86.5% |
| AFMD | Affimed N.V. | $660,000 | -10.8% | 400,000 | 0.0% | 0.01% | -16.7% | |
| FLGT | Fulgent Genetics, Inc. | $518,000 | +3.6% | 125,000 | 0.0% | 0.00% | 0.0% | |
| MTEM | Molecular Templates, Inc. | $379,000 | -34.5% | 72,412 | 0.0% | 0.00% | -40.0% | |
| AKTX | Sell | Akari Therapeutics, Plcsponsored adr | $115,000 | -81.4% | 58,770 | -82.7% | 0.00% | -80.0% |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $89,000 | +15.6% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $1,000 | -50.0% | 20,084 | 0.0% | 0.00% | – | |
| IMDZ | Exit | Immune Design Corp. | $0 | – | -148,937 | -100.0% | -0.00% | – |
| NVAX | Exit | Novavax, Inc. | $0 | – | -2,000,000 | -100.0% | -0.04% | – |
| Exit | Inotek Pharmaceuticals Corp.note 5.75% 8/1/2021 | $0 | – | -5,000,000 | -100.0% | -0.04% | – | |
| NKTR | Exit | Nektar Therapeutics | $0 | – | -275,396 | -100.0% | -0.25% | – |
| IDRA | Exit | Idera Pharmaceuticals, Inc. | $0 | – | -38,641,462 | -100.0% | -0.60% | – |
| ABLX | Exit | Ablynx NVsponsored adr | $0 | – | -2,176,802 | -100.0% | -1.01% | – |
| AVXS | Exit | AveXis, Inc. | $0 | – | -1,167,157 | -100.0% | -1.22% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.